Skip to main content
OpenTrials
Completed

NCT Number: NCT02166554

The Efficacy and Safety Study of a New Cross-linked Hyaluronan Hydrogel in the Reduction of Postsurgical Peritoneal Adhesions

The purpose of this study was to determine whether the new crosslinked hyaluronan hydrogel was safe to use, and was effective for the prevention/reduction of adhesion formation following gynecological surgery

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–45 year

Sex eligibility

Female

Study type

Interventional

Phase

Phase 1 / Phase 2

Primary location

Beijing Chao-Yang Hospital, Beijing, Beijing Municipality, China

Loading trial locations.

About this study

Postsurgical adhesions are a common medical complication of gynecologic and pelvic surgeries, and are frequently associated with chronic or recurrent pelvic pain, intestinal obstruction and infertility. This randomized, controlled, multicenter, clinical study was designed to evaluate the safety and performance of the new crosslinked hyaluronan hydrogel versus the standard of care for the reduction of postoperative adhesions in subjects undergoing laparoscopic surgeries. Subjects were scheduled to return at 9 weeks after the initial surgical procedure. At that time, a second-look laparoscopy was performed for postsurgical adhesion assessment. Adhesions were graded using a modified American Fertility Society (mAFS) scoring system.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Female.
  • Aged 18-45 years.
  • Been scheduled for removal of myomas, ovary cysts, endometriotic cysts or adhesions.
  • Been willing to comply with all aspects of the treatment and evaluation schedule.
  • Agreed to a second-look laparoscopic procedure to assess and lyse any adhesions formed at 9 weeks following the primary surgery.
  • Provided voluntary written informed consent.

Exclusion criteria

  • Acute or severe infection.
  • Autoimmune diseases such as diabetes etc.
  • Abnormal liver/renal and cardiovascular function
  • Abnormal blood coagulation
  • Medical histories of peripheral vascular disease, alcohol or drug abuse, and mental illness.
  • Known or suspected intolerance or hypersensitivity to hyaluronan or its derivatives.
  • Concurrent use of systemic antiinflammatory drugs.
  • Clinical evidence of cancer.
  • Use of anticoagulant, fibrin glue, other thrombogenic agents, or any other anti-adhesion agent during the procedure.
  • Concurrent peritoneal grafting or tubal implantation.

Treatment and study plan

Saline

Other

On the day of initial surgery

Cross-linked Hyaluronan Hydrogel

Device

On the day of the initial surgery

Other names: HyaRegen, Self Cross-linked Hyaluronan Gel

Primary outcomes

  1. The adhesion incidence under moderate/severe category

    Time frame: 9 weeks following primary laparoscopic gynecological surgery

    The patient percentage with modified American Fertility Society (mAFS) score (ovaries and tubes) more than 4 points.

Secondary outcomes

  1. modified American Fertility Society (mAFS) score

    Time frame: 9 weeks following primary laparoscopic gynecological surgery

    modified American Fertility Society (mAFS) score of ovaries/tubes

  2. Adhesion extent

    Time frame: 9 weeks following primary laparoscopic gynecological surgery

    Adhesion extent of ovaries/tubes

  3. Adhesion severity

    Time frame: 9 weeks following primary laparoscopic gynecological surgery

    Adhesion severity of ovaries/tubes

  4. The adhesion incidence under moderate/severe category

    Time frame: 9 weeks following primary laparoscopic gynecological surgery

    The patient percentage with modified American Fertility Society (mAFS) score (throughout abdominopelvic cavity) more than 4 points.

  5. modified American Fertility Society (mAFS) score

    Time frame: 9 weeks following primary laparoscopic gynecological surgery

    modified American Fertility Society (mAFS) score (throughout abdominopelvic cavity)

  6. Adhesion extent

    Time frame: 9 weeks following primary laparoscopic gynecological surgery

    Adhesion extent (throughout abdominopelvic cavity)

  7. Adhesion severity

    Time frame: 9 weeks following primary laparoscopic gynecological surgery

    Adhesion severity (throughout abdominopelvic cavity)

  8. Adverse events

    Time frame: Up to 9 weeks

    Safety evaluation was based on clinical laboratory tests, the type and severity of adverse events recorded throughout the study, etc.

Sponsors and collaborators

Lead sponsor

BioRegen Biomedical (Changzhou) Co., Ltd

Industry

Registry information

Official study title

The Efficacy and Safety of a New Cross-linked Hyaluronan Hydrogel in the Reduction of Postsurgical Adhesions After Laparoscopic Gynecological Surgery: a Randomized Controlled Trial

Acronym: BAP

Important dates

Study start
2011
Primary completion
2013
Study completion
2013
First posted
Jun 18, 2014
Registry last updated
Jun 18, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.